Global Inactivated Poliovirus Vaccine Market Size By Type (Human Diploid Cell, Monkey Kidney Cell), By Application (Public, Private), By Region, And Segment Forecasts, 2023 to 2032

The Global Inactivated Poliovirus Vaccine (IPV) Market was valued at USD 1.7 billion in 2023 and is projected to surpass USD 3.1 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The market is primarily driven by ongoing global immunization initiatives aimed at eradicating poliomyelitis, strong government and WHO-led vaccination campaigns, and rising awareness about vaccine-preventable diseases. The increasing number of routine immunization schedules including IPV and the demand for combination vaccines are further supporting the growth of this market.

Drivers:

1. Global Polio Eradication Initiatives:

Programs such as the Global Polio Eradication Initiative (GPEI) continue to drive demand for IPV, particularly in countries transitioning from oral polio vaccine (OPV) to IPV due to the latter’s higher safety profile.

2. Rising Vaccination Coverage:

Governments worldwide are investing in national immunization programs, increasing IPV administration in both public and private healthcare settings, thereby boosting market demand.

3. Preference for Combination Vaccines:

The integration of IPV into pentavalent or hexavalent combination vaccines has enhanced immunization compliance, creating new market opportunities and driving volume demand.

Restraints:

1. High Manufacturing and Storage Costs:

The production of IPV involves complex processes and biosafety containment requirements, resulting in higher costs that challenge affordability in low-income countries.

2. Uneven Access in Low-resource Regions:

Despite global initiatives, access to IPV remains inconsistent in certain regions due to infrastructure limitations and funding constraints.

Opportunity:

1. Expanding Pediatric Vaccine Markets in Emerging Economies:

With improving healthcare infrastructure and government support, countries in Asia-Pacific and Sub-Saharan Africa present lucrative opportunities for IPV deployment.

2. Shift from OPV to IPV Globally:

The global transition from OPV to IPV, driven by concerns over vaccine-derived poliovirus, offers a major opportunity for IPV manufacturers in both standalone and combination vaccine markets.

Market by System Type Insights:

Based on system type, Standalone IPV dominated the market in 2023 due to its critical role in early childhood immunization schedules. However, Combination IPV Vaccines (e.g., DTP-IPV, Pentavalent) are expected to register the fastest growth owing to increasing preference among healthcare providers and parents for multi-antigen formulations that reduce the number of injections and visits.

Market by End-use Insights:

In 2023, Public Sector Immunization Programs accounted for the largest market share, supported by extensive global vaccination initiatives and government-funded immunization drives. The Private Healthcare Sector is anticipated to witness notable growth due to rising uptake of premium combination vaccines in high-income countries.

Market by Regional Insights:

North America led the market in 2023 due to high immunization coverage and advanced healthcare infrastructure. However, the Asia-Pacific region is projected to be the fastest-growing market, driven by increasing birth rates, government support, and rising awareness in countries like India, Indonesia, and the Philippines. Latin America and Africa are also emerging as important regions with WHO-backed immunization funding.

Competitive Scenario:

Key players in the Global Inactivated Poliovirus Vaccine Market include:

Sanofi Pasteur

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

China National Biotec Group (CNBG)

AJ Biologics Sdn Bhd

Bharat Biotech International Ltd.

These companies are focusing on capacity expansion, development of combination vaccines, and partnerships with government health agencies and global organizations such as UNICEF and GAVI.

Key Developments:

In 2023, Bharat Biotech announced a partnership with a Southeast Asian government to supply combination IPV-containing vaccines.

Sanofi Pasteur expanded its IPV production facility in France in 2024 to meet rising global demand.

In 2025, Serum Institute of India began commercial production of low-cost combination vaccines containing IPV for African markets.

Scope of Work – Global Inactivated Poliovirus Vaccine Market

FAQs:

1) What is the current market size of the Global Inactivated Poliovirus Vaccine Market?

The market was valued at USD 1.7 billion in 2023.

2) What is the major growth driver of the Global Inactivated Poliovirus Vaccine Market?

The major growth driver is the global transition from oral to inactivated polio vaccines, supported by eradication efforts.

3) Which is the largest region during the forecast period in the Global Inactivated Poliovirus Vaccine Market?

North America held the largest share in 2023, but Asia-Pacific is expected to witness the highest growth during the forecast period.

4) Which segment accounted for the largest market share in the Global Inactivated Poliovirus Vaccine Market?

Standalone IPV accounted for the largest share in 2023, with combination vaccines poised for faster growth.

5) Who are the key market players in the Global Inactivated Poliovirus Vaccine Market?

Key players include Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India, CNBG, Bharat Biotech, and AJ Biologics.